## UTILITY PATENT APPLICATION TRANSMITTAL (Small Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. CEDAR-44649

Total Pages in this Submission //3

## TO THE ASSISTANT COMMISSIONER FOR PATENTS

**Box Patent Application** 

Washington, D.C. 20231

Transmitted herewith for filing under 35 U.S.C. 111(a) and 37 C.F.R. 1.53(b) is a new utility patent application for an invention entitled: MODULATING ACTIVATION OF LYMPHOCYTES AND SCREENING POTENTIAL IMMUNOMODULATING AGENTS BY TARGETING PITUITARY TUMOR TRANSFORMING GENE (PTTG) EXPRESSION AND/OR **FUNCTION** and invented by: Rostyslav Stoika, Gregory A. Horwitz, Xun Zhang and Shlomo Melmed If a CONTINUATION APPLICATION, check appropriate box and supply the requisite information: □ Continuation □ Divisional ☑ Continuation-in-part (CIP) of prior application No.: 09/569,956 Which is a: ☑ Continuation-in-part (CIP) of prior application No.: ☐ Continuation Divisional 08/894,251

filed as a national stage application, under 35 U.S.C. § 371, of international application PCT/US97/21463, which claims the priority filing date of U.S. Provisional Patent Application Serial No. 60/031,338.

## Enclosed are:

### **Application Elements**

- Filing fee as calculated and transmitted as described below 1. X
- 2. pages and including the following: Specification having
  - Descriptive Title of the Invention a. X
  - Cross References to Related Applications (if applicable) b. X
  - X Statement Regarding Federally-sponsored Research/Development (if applicable) C.
  - d. 🗆 Reference to Microfiche Appendix (if applicable)
  - $\mathbf{X}$ Background of the Invention
  - X Brief Summary of the Invention
  - Brief Description of the Drawings (if drawings filed) g. 🗷
  - h. 🔯 **Detailed Description**
  - i. 🔀 Claim(s) as Classified Below
  - i. 🔀 Abstract of the Disclosure

## the control of the co

## UTILITY PATENT APPLICATION TRANSMITTAL (Small Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. CEDAR-44649

Total Pages in this Submission

## **Application Elements (Continued)**

٥.		Drawing(s) (when necessary as prescribed by 35 OSC 173)									
	a.	☐ Formal b. 🗷 Informal Number of Sheets14									
4.	Ø	Oath or Declaration									
	a.	☐ Newly executed (original or copy)									
	b.	☐ Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional application only)									
	C.	☐ With Power of Attorney ☐ Without Power of Attorney									
	d.	DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. 1.63(d)(2) and 1.33(b).									
5.		Incorporation By Reference (usable if Box 4b is checked) The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.									
6.		Computer Program in Microfiche									
7.		Genetic Sequence Submission (if applicable, all must be included)									
	a.	□ Paper Copy									
	b.	☐ Computer Readable Copy									
	C.	Statement Verifying Identical Paper and Computer Readable Copy									
		Accompanying Application Parts									
8.		Assignment Papers (cover sheet & documents)									
9.		37 CFR 3.73(b) Statement (when there is an assignee)									
10.		English Translation Document (if applicable)									
11.		Information Disclosure Statement/PTO-1449									
12.		Preliminary Amendment									
13.	X	Acknowledgment postcard									
14.	X	Certificate of Mailing									
		☐ First Class 🗷 Express Mail (Specify Label No.): EL 537830543 US									

# that that the time same and the tent to the tent after the tent and the tent and the tent to the tent

## UTILITY PATENT APPLICATION TRANSMITTAL (Small Entity)

Docket No. CEDAR-44649

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Total Pages in this Submission

Accompanying Application Parts (Continued)											
15.											
16.											
17.	☐ Additional Enclosures (please identify below):										
Fee Calculation and Transmittal											
CLAIMS AS FILED											
For		#Filed	#Allowed	#Extra	Rate		Fee				
Total Claims			53	- 20 =	33	× \$9.00		\$297.00			
ndep. Claims			4	- 3 =	1	x \$40.00		\$40.00			
Multiple Dependent Claims (check if applicable)											
BASIC FEE											
OTHER FEE (specify purpose)											
						TOTAL FILIF	NG FEE	\$692.00			
□ A check in the amount of to cover the filing fee is enclosed. □ The Commissioner is hereby authorized to charge and credit Deposit Account No. as described below. A duplicate copy of this sheet is enclosed. □ Charge the amount of as filing fee. □ Credit any overpayment. □ Charge any additional filing fees required under 37 C.F.R. 1.16 and 1.17. □ Charge the issue fee set in 37 C.F.R. 1.18 at the mailing of the Notice of Allowance, pursuant to 37 C.F.R. 1.311(b).  Dated: October 13, 2000  Nisan A. Steinberg, Ph.D.											
cc:	13-1010										

"EXPRESS MAIL" (37 CFR 1.10) CERTIFICATE OF MAILING Applicant(s): Rostyslav Stoika, et al. **CEDAR-44649** Serial No. Filing Date Examiner Group Art Unito MODULATING ACTIVATION OF LYMPHOCYTES AND SCREENING POTENTIAL Vention: IMMUNOMODULATING AGENTS BY TARGETING PITUITARY TUMOR TRANSFORMING GENE (PTTG) EXPRESSION AND/OR FUNCTION I hereby certify that the following correspondence: Utility Patent Application Transmittal (Identify type of correspondence) is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 11.19 37 CFR 1.10 in an envelope addressed to: The Assistant Commissioner for Patents, Washington, D.C. 20231 October 13, 2000 (Date) Ann Weiss (Typed or Printed Name of Person Mailing Correspondence) (Signature of Person Mailing Correspondence) ("Express Mail" Mailing Label Number) Note: Each paper must have its own certificate of mailing.